GlassScriptPhysician profile
Harish K Dhingra
NPI 1710931530
$2,957.40
in general payments reported to CMS, 2019-2025
29 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $63.44 · 2021: $91.62 · 2022: $296 · 2023: $319 · 2024: $664 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $498.51 | 2019-2024 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $373.98 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Allergan, INC. | $315.39 | 2019 | |
| Abbott Laboratories | $263.00 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $246.39 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $134.74 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $128.06 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $96.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.08 | 2022-2024 | |
| Astellas Pharma US INC | $87.01 | 2019-2022 | |
| Amgen INC. | $84.68 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $80.89 | 2019-2024 | Airsupra |
| Shield Therapeutics INC | $76.33 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.41 | 2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $53.34 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $41.62 | 2022-2024 | Verquvo |
| Exact Sciences Corporation | $41.39 | 2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $40.09 | 2019 | |
| Lundbeck LLC | $32.84 | 2023-2024 | Rexulti |
| Sk Life Science, INC. | $25.37 | 2025 | |
| Acadia Pharmaceuticals INC | $21.83 | 2022 | |
| Corcept Therapeutics | $21.52 | 2022 | |
| Dexcom, INC. | $19.28 | 2021 | |
| Mannkind Corporation | $17.96 | 2019 | |
| Lilly USA, LLC | $17.58 | 2024 | Zepbound, Mounjaro |
| Cmp Pharma, INC. | $16.26 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.57 | 2022 | |
| Glaxosmithkline, LLC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harish Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.